Kura Oncology reports Phase 1a data on darlifarnib combo in RCC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. ASO
6. QCOM
7. IRT
8. SPY
9. EVMN
10. AAPL

Go back to Kura Oncology reports Phase 1a data on darlifarnib combo in RCC
(NASDAQ: KURA) Delayed: 12.21 -0.31 (2.48%)
Previous Close $12.52    52 Week High $8.90 
Open $12.50    52 Week Low $2.50 
Day High $12.61    P/E N/A 
Day Low $12.15    EPS $0.00 
Volume 700,532